Genome & Company Adjusts Stock Option Exercise Price and Increases Granted Shares (Amendment)

Amendment: Stock option grant adjusted: grantees 20→15, shares 71,750→117,000, exercise price 34,900→10,070 won.
Reason for lower exercise price: adjustment due to paid-in capital increase and stock dividend per contract.
Total outstanding options after amendment: 4,092,568 shares (previously 1,941,396).
Grantees: 15 employees (names omitted as individual grants <0.1% of total shares).
Fair value using binomial model: assumptions: prior day closing price 39,300 won, exercise price 10,070 won, risk-free rate 1.66%, expected volatility 56.41%.
Exercise period: Jan 1, 2022 to Dec 31, 2028.
Subject to audit results.